$MLRT
Metalert, Inc.

2024 Q3 Form 10-Q Financial Statement

#000149315224033153 Filed on August 19, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $52.03K $44.16K
YoY Change -39.32% -9.57%
Cost Of Revenue $32.72K $14.93K
YoY Change -61.81% -65.52%
Gross Profit $19.31K $29.23K
YoY Change 24981.82% 428.95%
Gross Profit Margin 37.12% 66.19%
Selling, General & Admin $63.15K $56.77K
YoY Change -10.56% -68.19%
% of Gross Profit 326.98% 194.21%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $153.1K $116.8K
YoY Change -39.62% -37.47%
Operating Profit -$133.7K -$87.59K
YoY Change -47.22% -51.68%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$64.09K -$66.26K
YoY Change -63.62% 142.79%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$197.8K -$153.9K
YoY Change -53.95% -26.24%
Net Earnings / Revenue -380.24% -348.39%
Basic Earnings Per Share -$0.01 $0.00
Diluted Earnings Per Share -$0.01 $0.00
COMMON SHARES
Basic Shares Outstanding 34.35M shares 33.85M shares
Diluted Shares Outstanding 34.19M shares 33.85M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $29.96K $30.23K
YoY Change -72.0% -33.92%
Cash & Equivalents $29.31K $29.58K
Short-Term Investments $649.00 $649.00
Other Short-Term Assets $4.079K $5.801K
YoY Change -14.47% 21.61%
Inventory $225.4K $226.7K
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $283.7K $280.0K
YoY Change -34.11% 133.53%
LONG-TERM ASSETS
Property, Plant & Equipment $11.16K $12.65K
YoY Change -67.29% -70.2%
Goodwill
YoY Change
Intangibles $219.9K $234.0K
YoY Change -21.32% 6972.91%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $231.0K $246.6K
YoY Change -26.32% 438.97%
TOTAL ASSETS
Total Short-Term Assets $283.7K $280.0K
Total Long-Term Assets $231.0K $246.6K
Total Assets $514.7K $526.6K
YoY Change -30.83% 217.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $198.1K $173.3K
YoY Change -3.81% 4.88%
Accrued Expenses
YoY Change
Deferred Revenue $7.646K $8.004K
YoY Change 18.54% 22.2%
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.624M $4.449M
YoY Change 11.13% 19.14%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.624M $4.449M
Total Long-Term Liabilities
Total Liabilities $4.757M $4.583M
YoY Change 10.65% 18.32%
SHAREHOLDERS EQUITY
Retained Earnings -$29.35M -$29.15M
YoY Change 3.18% 4.06%
Common Stock $3.435K $3.385K
YoY Change 7.78% 44.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.243M -$4.057M
YoY Change
Total Liabilities & Shareholders Equity $514.7K $526.6K
YoY Change -30.83% 217.9%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$197.8K -$153.9K
YoY Change -53.95% -26.24%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4372041 usd
CY2023Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
137028 usd
CY2024Q2 us-gaap Liabilities
Liabilities
4583460 usd
CY2023Q4 us-gaap Liabilities
Liabilities
4509069 usd
CY2024Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
13826 usd
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
24936 usd
CY2024Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
212894 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
206882 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
226720 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
231818 usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001375793
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-53046
dei Entity Registrant Name
EntityRegistrantName
MetAlert, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0493446
dei Entity Address Address Line1
EntityAddressAddressLine1
117 W. 9th Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1214
dei Entity Address City Or Town
EntityAddressCityOrTown
Los Angeles
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90015
dei City Area Code
CityAreaCode
(213)
dei Local Phone Number
LocalPhoneNumber
489-3019
dei Security12b Title
Security12bTitle
Common Stock, Par Value $0.0001
dei Trading Symbol
TradingSymbol
MLRT
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34345931 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29576 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68440 usd
CY2024Q2 us-gaap Accounts Receivable Net
AccountsReceivableNet
17240 usd
CY2023Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
17408 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
226720 usd
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
649 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
649 usd
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
5801 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
4339 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
279986 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
322654 usd
CY2024Q2 us-gaap Assets
Assets
526608 usd
CY2023Q4 us-gaap Assets
Assets
610195 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
264671 usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
usd
MLRT Gain On Settlement Of Debt
GainOnSettlementOfDebt
usd
CY2023Q2 us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
usd
us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
usd
CY2024Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
usd
us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
usd
us-gaap Share Based Compensation
ShareBasedCompensation
usd
MLRT Gains Losses On Settlement Of Debt And Accrued Interest
GainsLossesOnSettlementOfDebtAndAccruedInterest
usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
us-gaap Increase Decrease In Due To Officers And Stockholders Current
IncreaseDecreaseInDueToOfficersAndStockholdersCurrent
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
usd
MLRT Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
MLRT Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
shares
CY2023Q4 us-gaap Inventory Net
InventoryNet
231818 usd
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
233972 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
261761 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12650 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25780 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
173261 usd
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8004 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
6505 usd
CY2024Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
94020 usd
CY2023Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
102040 usd
CY2024Q2 us-gaap Other Short Term Borrowings
OtherShortTermBorrowings
15500 usd
CY2023Q4 us-gaap Other Short Term Borrowings
OtherShortTermBorrowings
12972 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4448960 usd
CY2024Q2 us-gaap Long Term Loans Payable
LongTermLoansPayable
134500 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2071000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33845931 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33845931 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32445931 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32445931 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
3385 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3245 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
25091372 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24844494 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-29151631 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28746629 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-4056852 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-3898874 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
526608 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
610195 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
92481 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
121532 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
20063 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
73680 usd
us-gaap Gross Profit
GrossProfit
72418 usd
us-gaap Gross Profit
GrossProfit
47852 usd
us-gaap Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
131801 usd
us-gaap Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
242494 usd
us-gaap Professional Fees
ProfessionalFees
67420 usd
us-gaap Professional Fees
ProfessionalFees
51923 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10859 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
-20 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
125939 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
113458 usd
us-gaap Operating Expenses
OperatingExpenses
336019 usd
us-gaap Operating Expenses
OperatingExpenses
407855 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-263601 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-360003 usd
MLRT Gain On Settlement Of Debt
GainOnSettlementOfDebt
44217 usd
us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
-34 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
20236 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
42219 usd
MLRT Interest Expense Income And Financing Costs
InterestExpenseIncomeAndFinancingCosts
-121165 usd
MLRT Interest Expense Income And Financing Costs
InterestExpenseIncomeAndFinancingCosts
-99691 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-141401 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-97727 usd
us-gaap Net Income Loss
NetIncomeLoss
-405002 usd
us-gaap Net Income Loss
NetIncomeLoss
-457730 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-405002 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-457730 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33845931 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33845931 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22896968 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22896968 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33672305 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33672305 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22096739 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22096739 shares
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-3902995 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-153858 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-4056852 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-3505487 usd
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
5779 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-208584 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-3708292 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-3898874 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
47024 usd
MLRT Issuance Of Preferred Stock For Financings
IssuanceOfPreferredStockForFinancings
200000 usd
us-gaap Net Income Loss
NetIncomeLoss
-405002 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-4056852 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3312877 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3312877 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
62315 usd
us-gaap Net Income Loss
NetIncomeLoss
-457730 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-3708292 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-3708292 usd
us-gaap Net Income Loss
NetIncomeLoss
-405002 usd
us-gaap Net Income Loss
NetIncomeLoss
-457730 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
43919 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
16670 usd
us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
-34 usd
us-gaap Share Based Compensation
ShareBasedCompensation
47024 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
20236 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
42219 usd
MLRT Gains Losses On Settlement Of Debt And Accrued Interest
GainsLossesOnSettlementOfDebtAndAccruedInterest
-27537 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-16680 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-168 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1038 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-5098 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-13647 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1463 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-3275 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-230134 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
113980 usd
MLRT Increase Decrease In Account Payable Related Parties
IncreaseDecreaseInAccountPayableRelatedParties
209438 usd
MLRT Increase Decrease In Account Payable Related Parties
IncreaseDecreaseInAccountPayableRelatedParties
132654 usd
MLRT Increase Decrease In Account Payable And Financing Costs
IncreaseDecreaseInAccountPayableAndFinancingCosts
56302 usd
MLRT Increase Decrease In Account Payable And Financing Costs
IncreaseDecreaseInAccountPayableAndFinancingCosts
-94518 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1499 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6300 usd
us-gaap Increase Decrease In Due To Officers And Stockholders Current
IncreaseDecreaseInDueToOfficersAndStockholdersCurrent
35000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-252915 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-155814 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3000 usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
46881 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
200000 usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
40000 usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
190000 usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
8019 usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
27791 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
14930 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
16722 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
217051 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
192368 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-38864 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
36554 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
68440 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8535 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29576 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
45089 usd
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
62315 usd
MLRT Debt Discount On Convertible Notes
DebtDiscountOnConvertibleNotes
8000 usd
MLRT Debt Discount On Convertible Notes
DebtDiscountOnConvertibleNotes
7150 usd
CY2024Q2 MLRT Working Capital
WorkingCapital
-4168974 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
92481 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
121532 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
92481 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
121532 usd
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
11599 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
11599 usd
us-gaap Standard Product Warranty Description
StandardProductWarrantyDescription
The Company’s warranty policy provides repair or replacement of products (excluding GPS Shoe devices) returned for defects within ninety days of purchase
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_844_eus-gaap--UseOfEstimates_zWuuYqMhkbvj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; vertical-align: baseline; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86A_zb4bDM9ANBCi">Use of Estimates</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; vertical-align: baseline; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; vertical-align: baseline; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the accompanying unaudited financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates include, but are not limited to, estimates related to revenue recognition, allowance for doubtful accounts, inventory valuation, tangible and intangible long-term asset valuation, warranty and other obligations and commitments. Estimates are updated on an ongoing basis and are evaluated based on historical experience and current circumstances. Changes in facts and circumstances in the future may give rise to changes in these estimates which may cause actual results to differ from current estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; vertical-align: baseline; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84E_eus-gaap--ConcentrationRiskCreditRisk_zHI5rxifoY9c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; vertical-align: baseline; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_865_z90vRLHufS2e">Concentrations</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; vertical-align: baseline; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; vertical-align: baseline; text-align: justify">We currently rely on two manufacturers to supply us with our GPS SmartSole and two manufacturers to supply us with the GPS device included in the GPS SmartSole. The loss of either of these manufacturers could severely impede our ability to manufacture the GPS SmartSole.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; vertical-align: baseline; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; vertical-align: baseline; text-align: justify">We currently rely on one manufacturer to supply us with our GPS GunAlert and one manufacturer to supply us with the GPS device included in the GPS GunAlert. The loss of this manufacturer could severely impede our ability to manufacture the GunAlert tracking solution. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; vertical-align: baseline; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; vertical-align: baseline; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2024, the Company had four customers representing approximately <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240630__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zqYlgHNxJRoi">36</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240630__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z3Qvyd6F8lN2">19</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240630__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zzZwDELzQOU8">17</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240630__srt--MajorCustomersAxis__custom--CustomerFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zSLDsbePq5He">12</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of sales, respectively, and three customers representing approximately <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240630__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zXAjqMEHPxrd">33</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240630__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zCdT9QpHm3Zd">12</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240630__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zyQd4OdmgGfk">11% </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of total accounts receivable, respectively. As of June 30, 2023, the Company had four customers representing approximately <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztzO2XRdQU5f">29</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zA99RhTfZB25">29</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zDygdOGuuHY5">15</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--MajorCustomersAxis__custom--CustomerFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zeY2umh2fVki">14</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of sales, respectively, and two customers representing approximately <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zBoGexVBaZD7">14</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, <span>and </span></span><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zoT4Amsj61S1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Concentration risk percentage">8</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of total accounts receivable, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; vertical-align: baseline; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
649 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
649 usd
CY2024Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
0 usd
CY2023Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
0 usd
CY2020Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
0 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
122533463 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
89040381 shares
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
MLRT Investment Owned Description
InvestmentOwnedDescription
The Company’s investments include marketable securities of two entities whereby the Company’s ownership is less than 5%.
CY2024Q2 us-gaap Marketable Securities
MarketableSecurities
649 usd
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
649 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
504384 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
488254 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12650 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25780 usd
us-gaap Depreciation
Depreciation
16130 usd
us-gaap Depreciation
Depreciation
16670 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
45493 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
17704 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
233972 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
261761 usd
CY2024Q2 us-gaap Loans Payable Current
LoansPayableCurrent
146195 usd
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
146195 usd
CY2024Q2 us-gaap Line Of Credit
LineOfCredit
7000 usd
CY2023Q4 us-gaap Line Of Credit
LineOfCredit
7000 usd
CY2024Q2 us-gaap Other Borrowings
OtherBorrowings
87020 usd
CY2023Q4 us-gaap Other Borrowings
OtherBorrowings
95040 usd
CY2024Q2 us-gaap Notes Payable
NotesPayable
240215 usd
CY2023Q4 us-gaap Notes Payable
NotesPayable
248235 usd
CY2022Q2 us-gaap Line Of Credit Facility Current Borrowing Capacity
LineOfCreditFacilityCurrentBorrowingCapacity
25000 usd
CY2022Q4 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
120000 usd
CY2024Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1518000 usd
CY2023Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1454142 usd
CY2024Q2 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
6000 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
6788 usd
CY2024Q2 us-gaap Debt Current
DebtCurrent
1518000 usd
CY2023Q4 us-gaap Debt Current
DebtCurrent
1484142 usd
CY2024Q2 us-gaap Other Loans Payable Current
OtherLoansPayableCurrent
15500 usd
CY2023Q4 us-gaap Other Loans Payable Current
OtherLoansPayableCurrent
12972 usd
CY2024Q2 us-gaap Other Loans Payable Long Term
OtherLoansPayableLongTerm
134500 usd
CY2023Q4 us-gaap Other Loans Payable Long Term
OtherLoansPayableLongTerm
137028 usd
CY2024Q2 us-gaap Other Loans Payable
OtherLoansPayable
150000 usd
CY2023Q4 us-gaap Other Loans Payable
OtherLoansPayable
150000 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
47024 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
846154 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
646154 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
200000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2024Q2 MLRT Bonus Declared Or Accrued
BonusDeclaredOrAccrued
0 usd
CY2023Q2 MLRT Bonus Declared Or Accrued
BonusDeclaredOrAccrued
0 usd

Files In Submission

Name View Source Status
0001493152-24-033153-index-headers.html Edgar Link pending
0001493152-24-033153-index.html Edgar Link pending
0001493152-24-033153.txt Edgar Link pending
0001493152-24-033153-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
mlrt-20240630.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mlrt-20240630_cal.xml Edgar Link unprocessable
mlrt-20240630_def.xml Edgar Link unprocessable
mlrt-20240630_lab.xml Edgar Link unprocessable
mlrt-20240630_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending